AngioDynamics expected to post 11-cent-per-share loss, revenue seen up 6.3%
LSEG mean estimate points to revenue of $80.5 million for the quarter ending Aug. 31, 2026, versus $75.71 million a year ago. Analyst estimate was unchanged over the past three months.
AngioDynamics, Inc. is expected to show a rise in quarterly revenue when it reports results on September 30 (estimated) for the period ending August 31 2026 The Latham New York-based company is expected to report a 6.3% increase in revenue to $80.5 million from $75.71 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data. LSEG's mean analyst estimate for AngioDynamics, Inc. is for a loss of 11 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for AngioDynamics, Inc. is $19.50, about 25.9% above its last closing price of $15.49 Previous quarterly performance (using preferred earnings measure in US dollars). QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI ENDING ARTESTIMAT ESTIMATE MET, SE % E® MISSED May.
31 2026 -0.09 -0.09 -0.07 Beat 22.2 Feb. 28 2026 -0.11 -0.11 0.02 Beat 118.2 Nov. 30 2025 -0.10 -0.10 0.00 Beat 100 Aug. 31 2025 -0.12 -0.12 -0.10 Beat 14.9 May.
-0.13 -0.12 -0.03 Beat 75 31 2025 Feb. 28 2025 -0.14 -0.13 0.03 Beat 123.1 Nov. 30 2024 -0.10 -0.11 -0.04 Beat 63.6 Aug. 31 2024 -0.15 -0.15 -0.11 Beat 25 This summary was machine generated September 28 at 12:32 GMT.
All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)